InspireMD (NYSE:NSPR) and Meihua International Medical Technologies (NASDAQ:MHUA) Critical Survey

InspireMD (NYSE:NSPR) and Meihua International Medical Technologies (NASDAQ:MHUA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares InspireMD and Meihua International Medical Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InspireMD	-350.35%	-55.12%	-46.95%
Meihua International Medical Technologies	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations for InspireMD and Meihua International Medical Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0	0	1	0	3.00
Meihua International Medical Technologies	0	0	0	0	N/A

InspireMD currently has a consensus target price of $4.85, suggesting a potential upside of 98.78%. Given InspireMD’s higher probable upside, research analysts plainly believe InspireMD is more favorable than Meihua International Medical Technologies.

Volatility & Risk

InspireMD has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Meihua International Medical Technologies has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Valuation and Earnings

This table compares InspireMD and Meihua International Medical Technologies’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InspireMD	$6.48 million	9.39	-$19.92 million	($0.76)	-3.21
Meihua International Medical Technologies	$97.10 million	0.23	$11.62 million	N/A	N/A

Meihua International Medical Technologies has higher revenue and earnings than InspireMD.

Insider and Institutional Ownership

44.8% of InspireMD shares are owned by institutional investors. Comparatively, 1.2% of Meihua International Medical Technologies shares are owned by institutional investors. 29.7% of InspireMD shares are owned by insiders. Comparatively, 66.6% of Meihua International Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Meihua International Medical Technologies beats InspireMD on 6 of the 11 factors compared between the two stocks.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

About Meihua International Medical Technologies

Meihua International Medical Technologies Co., Ltd. engages in the manufacture, sells, and marketing of medical consumables in the People's Republic of China. The company offers class I, II, and III disposable medical devices. Its products include non-bottled products, such as brushes and ID bracelets; and polyethylene bottled products, such as eye drop and tablet bottles, as well as electronic pumps. The company also distributes disposable medical devices sourced from other manufacturers to customers in China. In addition, it offers COVID-19 products comprising disposable medical masks. The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. It also exports its products to Europe, North America, South America, Asia, Africa, and Oceania. The company was founded in 1991 and is based in Yangzhou, the People's Republic of China. Meihua International Medical Technologies Co., Ltd. operates as a subsidiary of Bright Accomplish Limited.